NVO Stock Price, News and Analysis
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Market Cap: $210,863,304,681.08
Industry:
Track NVO stock with real-time alerts and market analysis
Current Price: $47.47
Novo Nordisk A/S
$47.47
-1.88%$-0.91
Major market announcement affects tech stocks across all sectors
Earnings report shows significant growth in quarterly revenue
Regulatory changes impact industry outlook for upcoming quarter